SCHEMBL644994

SCHEMBL644994

COC(=O)CCNC(=O)C(Cl)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
F9 P00740 1/20 0.44
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
ALDH1A1 P00352 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
PRSS1 P07477 1/20 0.43
CTSG P08311 1/20 0.43
CTRB1 P17538 1/20 0.43
CMA1 P23946 1/20 0.43
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NAAA Q02083 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7112889 0.79 CYP3A4 (0.53) CNR1CNR2ALDH1A1CYP3A4NAAA
SCHEMBL9472352 0.78 LMNA (0.45) CA12CA7CA9CA14F9
Hydrochloric Acid SCHEMBL11651001 0.76 CNR1 (0.46) CNR1CNR2ALDH1A1NAAAPOLB
SCHEMBL11845564 0.76 NAAA (0.43) CNR1CNR2ALDH1A1SMN1; SMN2NAAA
SCHEMBL28352839 0.76 KMT2A (0.47) CA12CA7CA9CA14ALDH1A1
SCHEMBL7330779 0.74 CTSS (0.54)
SCHEMBL7332020 0.74 MME (0.54) CNR1CNR2ALDH1A1HPGD
SCHEMBL13846307 0.74 CTSD (0.44) CNR1CNR2ALDH1A1LMNACYP2C19
SCHEMBL11776768 0.74 KMT2A (0.48) ALDH1A1CYP3A4CYP2D6SMN1; SMN2
SCHEMBL7398925 0.74 SLC15A1 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101326151-B Improved method for the production of ramipril SANOFI AVENTIS DEUTSCHLAND 2015-01-07 CN disclosed
US-8119375-B2 Method for the production of ramipril SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-02-21 US disclosed
US-20090017509-A1 METHOD FOR THE PRODUCTION OF RAMIPRIL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-01-15 US disclosed
CN-101326151-A Improved method for the production of ramipril SANOFI AVENTIS DEUTSCHLAND (DE) 2008-12-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090017509-A1 METHOD FOR THE PRODUCTION OF RAMIPRIL REN, PDE8B, PDE3A CA12 4086/4885CA7 2086/4885CA9 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.